Search Results for: Organigram
Organigram Makes First Strategic U.S. Investment in Phylos Bioscience to Commercialize THCV and Scale Seed Based Production
Phylos is a recognized leader in seed genetics with a growing IP portfolio including the…
Organigram to Enter German Market Supplying Sanity Group
Organigram to supply the medical division of German cannabis company Sanity Group with high-quality medical…
Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”), a leading Canadian licensed producer of…
Organigram Reports Second Quarter Fiscal 2022 Results
HIGHLIGHTS Achieved gross revenue of $43.9 million, up 128% from the same prior-year period and…
Organigram to Report Second Quarter 2022 Results on April 12, 2022
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the…
Organigram Reports First Quarter Fiscal 2022 Results
$30.4 million net revenue represents a record for the Company as it solidifies #4 market…
Organigram Reports Fourth Quarter Fiscal 2021 Results
Continued growth in net revenue and increased market share Achieved a 7% share of market…
Organigram Provides Corporate Update
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) (the “Company” or “Organigram”), the parent company of…
Organigram Appoints Beena Goldenberg as Chief Executive Officer
Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI), the parent company of…
Organigram Reports Third Quarter Fiscal 2021 Results
Grew gross revenue 51% sequentially to $29.1 million in Q3 2021 from Q2 2021 and…
Recent Comments